A Phase 1/2 interventional study of Phenylephrine Hydrochloride in Mitral Regurgitation, sponsored by Montefiore Medical Center. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.
Sponsored by Montefiore Medical Center · Phase 1/2, Interventional, and Diagnostic
IRB Approval lapsed, study being terminated due to slow enrollment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 118 studies in Mitral Valve Insufficiency with a site in United States — 33 open to participants now, 53 under way, none of them phase 3. Mitral Valve Insufficiency · United States.
Among the 118 studies in Mitral Valve Insufficiency with a site in United States, this one is the 75th largest by enrollment of the 81 interventional ones that give a count, is one of 11 that started in 2020, is one of 3 in phase 1/2, and was the 80th registered.
471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.
Browse Mitral Valve Insufficiency studies →33 of the 118 studies in Mitral Valve Insufficiency with a site in United States are open now. Recruiting first, the newest first:
Capstan Medical · Sites in United States
Ages 18+
Abbott Medical Devices · Sites in United States
Ages 18+
Polares Medical SA · Sites in United States
Ages 21+
InnovHeart · Sites in United States
Ages 18+
Nyra Medical, Inc. · Sites in United States
Ages 21+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
118 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 4 · Phase 4 4
First in 1992; this study’s year is marked. 11 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 8 is below the median of 69 across 280 interventional studies indexed under Mitral Valve Insufficiency.
Median enrollment 60 across the 81 interventional studies, 200 across the 37 observational. Of the 52 that completed or were terminated, 26 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
62 of 118 have an industry lead sponsor. The 10 most frequent:
Montefiore Medical Center is the lead sponsor of 417 studies on the registry; 69 are open to participants now.
Of its 89 completed or terminated interventional studies of FDA-regulated products, 77 (87%) have results posted.
Montefiore Medical Center has 1 study filed under Mitral Valve Insufficiency — fewer than ten, so there is no comparison to draw.
13 of the studies in Mitral Valve Insufficiency with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04408430Mayra GuerreroThe MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves). | 2026-12 |
| NCT07655505Intuitive SurgicalUse of Force Feedback Instruments With the da Vinci Surgical System, Model IS5000 for Mitral Valve Repair | 2026-12-31 |
| NCT05061004Abbott Medical DevicesCephea Early Feasibility Study | 2026-12-31 |
| NCT03142152Cardiac Dimensions, Inc.The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR | 2026-12-31 |
| NCT06738615Atlantic Health SystemAssessing the Relationship Between Symptoms and Mitral Regurgitnant. Severity | 2027-01-02 |
Add all 13 to your calendar (.ics) → With an account.
Among the 118 studies in Mitral Valve Insufficiency with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The study proposes to develop a phenylephrine protocol to be used during transesophageal echocardiography (TEE), whereby intravenous phenylephrine would be used to increase afterload with the intent to mimic the awake hemodynamic profile and variation that occurs with normal physical activity. The expectation is to see changes in severity of Mitral Regurgitation (MR) grade with increasing afterload, which in turn can provide more accurate quantification of MR severity to assist in clinical decision making.
Routine echocardiography which is used to assess the severity of mitral regurgitation, sometimes underestimates the severity of mitral regurgitation, due to hemodynamic variations that occurs with normal physical activity and under the effect of sedation which is used to perform transesophageal echocardiography. By using phenylephrine during transesophageal echocardiography, the study intends to offset the hemodynamic variation that occurs with sedation and better assess the severity of mitral regurgitation, which would further assist in clinical decision-making regarding treatment. The goal of this study is to compare the severity of mitral regurgitation grade before and after the administration of phenylephrine during transesophageal echocardiography and to demonstrate a 25% increase in severity of mitral regurgitation grade compared to the baseline conditions, following the administration of phenylephrine.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The following patients will be excluded from the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Phenylephrine is available as phenylephrine hydrochloride injection, 10 mg/mL in 1 mL vial. For intravascular bolus administration, the investigators will prepare a solution containing 100 mcg/mL of phenylephrine hydrochloride, by withdrawing 10 mg (1ml of 10mg/mL) of phenylephrine injection and diluting with 99 mL of 5% dextrose injection or 0.9% sodium chloride injection. A 20 mcg intravenous test dose of phenylephrine will be administered by the cardiologist performing the TEE. BP will be monitored after each bolus of phenylephrine. Subsequent phenylephrine injections will then be administered in 50 mcg aliquots every 10-15 minutes, instead of 40 mcg, until the mean arterial blood pressure (MAP) increases by ≥ 20 mm Hg from the baseline MAP, making sure not to exceed a MAP of 100 mmHg. Once a desired blood pressure has been achieved and maintained, echocardiographic evaluation of mitral regurgitation would be performed.
Drug: Phenylephrine Hydrochloride
Phenylephrine hydrochloride injection (10 mg/mL) was diluted to 100 mcg/mL (10 mg in 99 mL of 5% dextrose or 0.9% sodium chloride) for intravenous bolus administration. A 20 mcg test dose was administered by the cardiologist performing the TEE, followed by 50 mcg boluses every 10-15 minutes until mean arterial pressure (MAP) increased by ≥20 mmHg from baseline MAP, without exceeding a MAP of 100 mmHg. Blood pressure was monitored after each bolus.
Number of Patients With Greater Than 25% Increase in Mitral Regurgitant Volume (RVol)
The purpose of this study is to compare the echocardiographic parameters of MR grade before and after the use of phenylephrine during transesophageal echocardiography (TEE) and to document a change in echocardiographic parameters of MR grade after the use of phenylephrine. RVol is a measure of volume overload and represents the total volume of blood leaking backward into the left atria each beat. RVol will be quantitatively graded by the Proximal Isovelocity Surface Area (PISA) method on TEE, before and after phenylephrine administration. Participants were counted if post-phenylephrine RVol increased by greater than 25% from pre-phenylephrine RVol.
Time frame: Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours
Change in Effective Regurgitant Orifice Area (ERO)
The purpose of this study is to compare the echocardiographic parameters of MR grade before and after the use of phenylephrine during transesophageal echocardiography (TEE) and to document a change in echocardiographic parameters of MR grade after the use of phenylephrine. ERO reflects the size of the regurgitant lesion and measures lesion severity. ERO is measured on TEE and graded using the PISA method (regurgitant flow = 2 × π × r² × aliasing velocity), before and after phenylephrine administration. Change is calculated as post-phenylephrine ERO minus pre-phenylephrine ERO and reported in square centimeters (cm²). Positive values indicate an increase in ERO area.
Time frame: Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours
Change in 3D Vena Contracta Diameter
The purpose of this study is to compare the echocardiographic parameters of MR grade before and after the use of phenylephrine during transesophageal echocardiography (TEE) and to document a change in echocardiographic parameters of MR grade after the use of phenylephrine administration. Change in vena contracta diameter, assessed before and after phenylephrine, will be measured in millimeters (mm) by 3D TEE. Change is calculated as post-phenylephrine value minus pre-phenylephrine value and reported in millimeters (mm). Positive values indicate an increase in vena contracta diameter.
Time frame: Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours
Change in Visual Mitral Regurgitation Grade
The purpose of this study is to compare the echocardiographic parameters of MR grade before and after the use of phenylephrine during transesophageal echocardiography (TEE) and to document a change in echocardiographic parameters of MR grade after the use of phenylephrine administration. Semi-quantitative visual MR is assessed during TEE before and after phenylephrine and graded on a 4-point scale ranging from 1 ("mild") to 4 ("severe"), integrating PISA-derived ERO/RVol and 3D vena contracta. Change calculated as post-phenylephrine grade minus pre-phenylephrine grade. Positive values indicate worsening MR grade.
Time frame: Baseline (pre-phenylephrine) and after phenylephrine administration during the same TEE procedure, up to 2 hours
Eligibility depended partly on the severity of Mitral Regurgitation (MR) seen on the baseline Transesophageal Echocardiogram (TEE).
| Milestone | Phenylephrine Hydrochloride |
|---|---|
| Started | 8 |
| Completed | 2 |
| Not completed | 6 |
| Withdrew: Baseline mr too severe on baseline tee | 5 |
| Withdrew: Adverse event | 1 |
The purpose of this study is to compare the echocardiographic parameters of MR grade before and after the use of phenylephrine during transesophageal echocardiography (TEE) and to document a change in echocardiographic parameters of MR grade after the use of phenylephrine. RVol is a measure of volume overload and represents the total volume of blood leaking backward into the left atria each beat. RVol will be quantitatively graded by the Proximal Isovelocity Surface Area (PISA) method on TEE, before and after phenylephrine administration. Participants were counted if post-phenylephrine RVol increased by greater than 25% from pre-phenylephrine RVol.
| Participants | Phenylephrine Hydrochloride |
|---|---|
| Number of Patients With Greater Than 25% Increase in Mitral Regurgitant Volume (RVol) | 2 |
The purpose of this study is to compare the echocardiographic parameters of MR grade before and after the use of phenylephrine during transesophageal echocardiography (TEE) and to document a change in echocardiographic parameters of MR grade after the use of phenylephrine. ERO reflects the size of the regurgitant lesion and measures lesion severity. ERO is measured on TEE and graded using the PISA method (regurgitant flow = 2 × π × r² × aliasing velocity), before and after phenylephrine administration. Change is calculated as post-phenylephrine ERO minus pre-phenylephrine ERO and reported in square centimeters (cm²). Positive values indicate an increase in ERO area.
| square centimeters (cm²) | Phenylephrine Hydrochloride |
|---|---|
| Change in Effective Regurgitant Orifice Area (ERO) | 0.08 ± 0.00 |
The purpose of this study is to compare the echocardiographic parameters of MR grade before and after the use of phenylephrine during transesophageal echocardiography (TEE) and to document a change in echocardiographic parameters of MR grade after the use of phenylephrine administration. Change in vena contracta diameter, assessed before and after phenylephrine, will be measured in millimeters (mm) by 3D TEE. Change is calculated as post-phenylephrine value minus pre-phenylephrine value and reported in millimeters (mm). Positive values indicate an increase in vena contracta diameter.
| millimeters | Phenylephrine Hydrochloride |
|---|---|
| Change in 3D Vena Contracta Diameter | 1.0 ± 0.5 |
The purpose of this study is to compare the echocardiographic parameters of MR grade before and after the use of phenylephrine during transesophageal echocardiography (TEE) and to document a change in echocardiographic parameters of MR grade after the use of phenylephrine administration. Semi-quantitative visual MR is assessed during TEE before and after phenylephrine and graded on a 4-point scale ranging from 1 ("mild") to 4 ("severe"), integrating PISA-derived ERO/RVol and 3D vena contracta. Change calculated as post-phenylephrine grade minus pre-phenylephrine grade. Positive values indicate worsening MR grade.
| units on a scale | Phenylephrine Hydrochloride |
|---|---|
| Change in Visual Mitral Regurgitation Grade | 1.0 ± 0.0 |
Mitral regurgitant volume per beat measured by the PISA method during transesophageal echocardiography, before and after phenylephrine administration. Change calculated as post-phenylephrine RVol minus pre-phenylephrine RVol. Positive values indicate an increase in regurgitant volume.
| milliliters | Phenylephrine Hydrochloride |
|---|---|
| Change in Mitral Regurgitant Volume (RVol) | 24 ± 9 |
Collected over From start of the study TEE procedure through up to 2 hours after phenylephrine administration (duration of study participation). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phenylephrine Hydrochloride | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| Event | Phenylephrine Hydrochloride |
|---|---|
| Severe HypertensionVascular disorders | 1/8 |
| BradycardiaCardiac disorders | 1/8 |
Baseline data provided for all eight enrolled participants who signed informed consent. Race and ethnicity were recorded as a single combined category.
| Age, Continuous(years) | Phenylephrine Hydrochloride |
|---|---|
| Mean | 68 ± 12 |
| Sex: Female, Male(Participants) | Phenylephrine Hydrochloride |
|---|---|
| Female | 5 |
| Male | 3 |
| Race/Ethnicity, Customized(Participants) | Phenylephrine Hydrochloride |
|---|---|
| Black | 4 |
| Hispanic | 3 |
| Undetermined | 1 |
| Region of Enrollment(participants) | Phenylephrine Hydrochloride |
|---|---|
| United States | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2020 to primary completion in Jul 2022, 19 months.
Results were first posted in Nov 2026, 4 years 3 months after primary completion.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Jun 2026 → Jul 2022 and completion Jun 2026 → Jul 2022.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
IRB Approval lapsed, study being terminated due to slow enrollment
IRB Approval lapsed, study being terminated due to slow enrollment
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Phenylephrine